The management of end stage renal disease inherently carries a large treatment burden for the patient and having an iron-based phosphate binder
with such an apparently positive safety and efficacy profile at this stage of development suggests the product could be of high clinical value to both doctors and patients in the future.
Among recently treated dialysis patients, Renvela tablets was the most commonly prescribed phosphate binder
, claiming a majority of the patient share in the fourth quarter of 2013.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that with the launch today in Spain of FOSRENOL (lanthanum carbonate), a non-calcium phosphate binder
, Shire is celebrating the completion of the launch roll-out in the major European markets.
Perceptions of Velphoro and Zerenex Uniqueness: Just over one-half of surveyed nephrologists report that Velphoro and Zerenex are highly unique compared with currently available phosphate binders
5), (9) FOSRENOL has the most extensive long-term safety data package of any phosphate binder
and is generally well tolerated.
Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder
Velphoro, which was approved by the FDA in November 2013 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Shire is committed to offering its effective phosphate binder
, FOSRENOL, to kidney patients who need protection from the complications of elevated serum phosphorus," said Joseph Schlitz, vice president, U.
1) Phosphate binders
are used to treat hyperphosphataemia (unusually high levels of phosphorous in the blood), which, if not managed successfully, can lead to serious health consequences including increased rates of cardiovascular morbidity and mortality and other complications.
There are more than 12 marketed products for the treatment of CKD, including angiotensin II receptor blockers, angiotensin converting enzyme (ACE) inhibitors, phosphate binders
, erythropoietin (EPO) and iron replacement products.
One quarter of dialysis patients reported problems taking their phosphate binders
and around one third reported missing phosphate doses at least once a week(8)
2013 report, the third ChartTrends dialysis report that has published since the dialysis bundle legislation was implemented in January 2011, finds that physicians are also initiating phosphate binders
at higher serum phosphorous levels compared to last year.
Renal osteodystrophy: Comparison of evolution over 1 and 2 years during treatment with lanthanum carbonate or standard phosphate binders